Dose comparison study of pegylated interferon-α-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 3, 2009, Pages 366-371

  Kawaoka, Tomokazu ^b   Kawakami, Yoshiiku ^a,b   Tsuji, Keiji ^c   Ito, Hiroyuki ^d   Kitamoto, Mikiya ^e   Aimitsu, Shiomi ^f   Kawakami, Hiroiku ^g   Jeong, Soo Cheol ^b   Imamura, Michio ^b   Aikata, Hiroshi ^b   Takahashi, Shoichi ^b   Chayama, Kazuaki ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA CITY ASA HOSPITAL   (Japan)

^d Saiseikai Kure Hospital   (Japan)

^e Hiroshima Prefecture Hiroshima Hospital   (Japan)

^f ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^g Kawakami Clinic   (Japan)

Author keywords

Hepatitis C virus genotype 2; Low dose pegylated interferon; Ribavirin; Side effect; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 63049139128     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05650.x     Document Type: Article

References (31)

1. Alter MJ. Epidemiology of hepatitis c in The West. Semin Liver Dis. 1995 15 : 5 14.
2. Poynard T, Bedossa P, Opolon P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997 349 : 825 32.
3. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990 12 : 671 5.
4. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 1993 28 : 1797 801.
5. Takano S, Yokosuka O, Imazeki F et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995 21 : 650 5.
6. Shiratori Y, Shiina S, Imamura M et al. Characteristic difference of hepatocellular carcinoma between hepatitis-B and C-viral infection in Japan. Hepatology 1995 22 : 1027 33.
7. Tomimatsu M, Ishiguro N, Taniai M et al. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 1993 72 : 683 8.
8. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med 1998 339 : 1485 92.
9. Poynaud T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 352 : 1426 32.
10. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000 343 : 1666 72.
11. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000 343 : 1673 80.
12. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001 34 : 395 403.
13. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001 33 : 433 8.
14. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon-2b plus ribavirin compared with interferon-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 65.
15. Fried MW, Shiffman M, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med 2002 347 : 975 82.
16. Glue P, Rouzier-Panis R, Raffanel C et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000 32 : 647 53.
17. Meyer-Wyss B, Rich P, Egger H. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. J. Viral. Hepat. 2006 13 : 457 65.
18. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 2005 352 : 2609 17.
19. Desmet VJ, Gerber M, Hoofnagle JH et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 20.
20. Rumi MG, Aghemo A, D'Ambrosio R et al. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antivir Ther 2007 12 : 1033 40.
21. Zeuzem S. Clinical implications of hepatitis C viral kinetics. J. Hepatol. 1999 31 (Suppl 1 61 4.
22. Bekkering FC, Stalgis C, McHutchison JG et al. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001 33 : 419 23.
23. Bjøro K, Bell H, Hellum KB et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: A randomized multicentre study. Scand. J. Gastroenterol. 2002 37 : 226 32.
24. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 2007 357 : 124 34.
25. Zeuzeml S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 2004 40 : 993 9.
26. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J. Viral. Hepat. 2008 15 : 475 81.
27. Sulkowski M, Lawitz E, Shiffman ML et al. Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIB study. J. Hepatol. 2008 48 (Suppl 2 S370 371.
28. Prati D, Zanella A, Zanuso F et al. Sustained response to interferon-a2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. J. Viral. Hepat. 2000 7 : 352 60.
29. Casiraghi MA, De Paschale M, Romano L et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004 39 : 90 6.
30. Uka K, Suzuki F, Akuta N et al. Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. J. Gastroenterol. 2006 41 : 470 5.
31. Akuta N, Suzuki F, Tsubota A et al. Efficacy of interferon monotherapy to 394 consecutive naïve cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J. Hepatol. 2002 37 : 831 6.